Revision as of 21:41, 12 December 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

14 regimens on this page 15 variants on this page

Neuroblastoma is a rare cancer but is the most common malignancy of infancy. Most of our contributors are adult oncologists, please consider expanding this page!

Low-risk

Intermediate-risk

High-risk

Dinutuximab, GM-CSF, IL-2, Isotretinoin

Regimen

Study	Evidence	Comparator	Efficacy
Yu et al. 2010 (COG ANBL0032)	Phase III	Isotretinoin	Seems to have superior OS

Immunotherapy

References

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. link to original article PubMed

@@ Line 18: / Line 18: @@
 =High-risk=
-==Dinutuximab, GM-CSF, IL-2, and Isotretinoin {{#subobject:231faf|Regimen=1}}==
+==Dinutuximab, GM-CSF, IL-2, Isotretinoin {{#subobject:231faf|Regimen=1}}==
-''Phase III results announced but no trial published in the peer-reviewed literature, yet.''
+===Regimen {{#subobject:abc626|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
+|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
+|-
+|[http://www.nejm.org/doi/full/10.1056/NEJMoa0911123 Yu et al. 2010 (COG ANBL0032)]
+|style="background-color:#00cd00"|Phase III
+|Isotretinoin
+|style="background-color:#00cd00"|Seems to have superior OS
+|-
+|}
+====Immunotherapy====
+*[[Dinutuximab (Unituxin)]]
+*[[Sargramostim (Leukine)]]
+*[[Aldesleukin (Proleukin)]]
+*[[Isotretinoin (Accutane)]]
 ===References===
-# Dinutuximab Approved for High-Risk Neuroblastoma. Cancer Discov. 2015 Apr 7. [Epub ahead of print] [http://cancerdiscovery.aacrjournals.org/content/early/2015/04/07/2159-8290.CD-NB2015-044.long link to article] [https://www.ncbi.nlm.nih.gov/pubmed/25851859 PubMed]
+# Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. [http://www.nejm.org/doi/full/10.1056/NEJMoa0911123 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20879881 PubMed]
 [[Category:Chemotherapy regimens]]
 [[Category:Pediatric oncology regimens]]

Difference between revisions of "Neuroblastoma"